These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19457654)

  • 1. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    Uchida K; Danenberg PV; Danenberg KD; Grem JL
    BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
    Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
    Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
    Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
    Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
    Int J Cancer; 2006 Jun; 118(12):3084-8. PubMed ID: 16425285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
    Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
    Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
    Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
    Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
    Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
    Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
    Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Sasaki H; Saito T
    Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
    Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
    Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
    Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
    Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
    Kawabata Y; Nishi T; Kidani A; Tajima Y
    Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Takahashi T; Nihei Z; Sugihara K; Sasaki Y; Hirayama R
    Br J Cancer; 2003 Oct; 89(8):1486-92. PubMed ID: 14562021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.